285 Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors by Marcus Butler, David Hong, Ryan Sullivan, Matthew Frigault, Sarah Boross-Harmer, Ecaterina Dumbrava, Jean-Marc Navenot, Svetlana Fayngerts, Jane Bai, Elliot Norry, Paula Fracasso, Russell Pachynski, Partow Kebriaei, Amy Sauer, Francine Brophy

376 Radiation sub-study to characterize safety and tolerability of low-dose radiation in combination with afami-cel in patients with advanced cancers (NCT03132922) by Ruoxi Wang, David Hong, James Welsh, Stavros Rafail, Hampartsoum Barsoumian, Jean-Marc Navenot, Jane Bai, Amy Sauer, Quan Lin, Danxia Ke, Nahum Puebla Osorio, Bryan Jackson, Marisa Rosenberg, Cheryl McAlpine, Robyn Broad, Ashley Liddle, Hassan Danesi

Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors by David S. Hong, Marcus O. Butler, Russell K. Pachynski, Ryan Sullivan, Partow Kebriaei, Sarah Boross-Harmer, Armin Ghobadi, Matthew J. Frigault, Ecaterina E. Dumbrava, Amy Sauer, Francine Brophy, Jean-Marc Navenot, Svetlana Fayngerts, Zohar Wolchinsky, Robyn Broad, Dzmitry G. Batrakou, Ruoxi Wang, Luisa M. Solis, Dzifa Yawa Duose, Joseph P. Sanderson, Andrew B. Gerry, Diane Marks, Jane Bai, Elliot Norry, Paula M. Fracasso

Get full text